

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: <b>A61K 9/08, A61K 31/48, A61K 47/02, A61K 47/10, A61P 25/06</b>	<b>A2</b>	(11) International Publication Number: <b>WO 00/57851</b> (43) International Publication Date: 05 October 2000 (05.10.2000)
---	-----------	--

(21) International Application Number: <b>PCT/US00/06657</b>	<b>Published</b>
(22) International Filing Date: <b>15 March 2000 (15.03.2000)</b>	
(30) Priority Data: <b>60/126,333 26 March 1999 (26.03.1999) US</b>	
(60) Parent Application or Grant <b>POZEN INC. [/]; () PLACHETKA, John, R. [/]; () GILBERT, Donna [/]; () SANZO, Michael, A.; ()</b>	

- (54) Title: **HIGH POTENCY DIHYDROERGOTAMINE COMPOSITIONS**  
(54) Titre: **COMPOSITIONS DE DIHYDROERGOTAMINE A HAUTE ACTIVITE**

## (57) Abstract

The present invention is directed to improved formulations for dihydroergotamine in which the drug is present at a concentration of at least 2.9 mM. The invention encompasses methods for using these formulations in treating patients for migraine headaches and the packaging of formulation into prefilled syringes for self-administration by patients.

## (57) Abrégé

L'invention concerne des formulations améliorées de la dihydroergotamine dans lesquelles le médicament présent à une concentration d'au moins 2,9 mM. Sont également traités des procédés d'utilisation de ces formulations pour le traitement de patients affectés par des migraines et l'emballage desdites formulations en seringues à préremplissage permettant aux patients de s'administrer eux-mêmes le médicament.

**Best Available Copy**

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : <b>A61K 9/08, 47/02, 47/10, 31/48, A61P 25/06</b>		<b>A2</b>	(11) International Publication Number: <b>WO 00/57851</b>
			(43) International Publication Date: 5 October 2000 (05.10.00)
(21) International Application Number: <b>PCT/US99/06657</b>		(61) Designated States: All, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GH, GI, GM, HP, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LP, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, ST, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SE, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, ST, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: <b>15 March 2000 (15.03.00)</b>		<b>Published</b> <i>Without international search report and to be republished upon receipt of that report</i>	
(30) Priority Data: <b>50/126,233 26 March 1999 (26.03.99) US</b>			
(71) Applicant: POZEN INC. (US/US); Suite 340, 6350 Quadrangle Drive, Chapel Hill, NC 27514 (US).			
(72) Inventors: FLACHETKA, John, R.; 321 Silver Creek Trail, Chapel Hill, NC 27514 (US). GILBERT, Donna; 504 Edgewater Circle, Chapel Hill, NC 27516 (US).			
(74) Agent: SANZO, Michael, A.; Winsa & Elkins L.L.P., 3500 First City Tower, 1001 Fannin, Houston, TX 77002-6760 (US).			
(54) Title: <b>HIGH POTENCY DIHYDROERGOTAMINE COMPOSITIONS</b>			
(57) Abstract  The present invention is directed to improved formulations for dihydroergotamine in which the drug is present at a concentration of at least 2.9 mM. The invention encompasses methods for using these formulations in treating patients for migraine headaches and the packaging of formulation into prefilled syringes for self-administration by patients.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LI	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	ME	The Former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Ivory Coast	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MT	Malta	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	MY	Malaysia	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LA	Laos	RO	Romania		
CZ	Czech Republic	LT	Lithuania	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

**Description**

5

10

15

20

25

30

35

40

45

50

55

WO 00/57851

PCT/US00/06657

## High Potency Dihydroergotamine Compositions

### Field of the Invention

The present invention encompasses pharmaceutical compositions containing dihydroergotamine (DHE) and methods in which these pharmaceutical compositions are administered to patients, particularly for the treatment of migraine headaches. The invention also encompasses the packaging of injection syringes prefilled with DHE preparations.

### Background of the Invention

Dihydroergotamine (DHE) is an ergot alkaloid that was identified as an effective treatment for migraine nearly fifty years ago (Raskin, *Neurology* 36:995-997 (1986); Silberstein, *et al.*, *Headache* 30:334-339 (1990); Saadah, *Headache* 32:18-20 (1992); and Winner, *Headache* 33:471-475 (1993)). It is presently marketed both as an injectable product (DHE 45<sup>®</sup>) and as a nasal spray (Migranal<sup>®</sup>). DHE is typically administered by intramuscular or intravenous injection (Belgrade, *et al.*, *Neurology* 39:590-592 (1989); Winner, *Headache* 33:471-475 (1993)), but it is also effective when given subcutaneously (Klappen, *et al.*, *Headache* 32:21-23 (1992); Winner, *et al.*, *Arch. Neurol.* 53:180-184 (1996); and Becker, *et al.*, *Headache* 36:144-148 (1996)).

Although effective in the treatment of migraine, DHE administration is often accompanied by side effects such as nausea, vomiting and chest pain (Winner, *et al.*, *Arch. Neurol.* 53:180-184 (1996)). At least one side effect, nausea, occurs more frequently after intravenous administration than after intramuscular or intranasal administration. When given subcutaneously at a concentration of only 1.5 mM, DHE has been reported to cause nausea in nearly 16% of treated patients (Winner, *et al.*, *Arch. Neurol.* 53: 80-184 (1996)). New drug formulations and methods for administering DHE which reduce its adverse side effects would represent a significant advance in migraine therapy.

### Summary of the Invention

The present invention is based upon the discovery that the side effect profile of DHE can be unexpectedly improved when the drug is administered to patients in a novel, high-potency form. More particularly, it has been found that when the concentration of DHE in compositions is increased from 1.5 mM (the concentration in commercially available injectable preparations)

WO 00/57851

PC1/US00/06657

2

to 2.9 mM or more, side effects, particularly nausea, are reduced even though the total quantity of DHE administered remains constant.

In its first aspect, the invention is directed to a pharmaceutical composition in unit dose form containing DHE dissolved in a pharmaceutically acceptable liquid vehicle. The concentration of DHE must be at least 2.9 mM and a "unit dose" should contain a sufficient amount to be effective in the symptomatic treatment of migraine headache when administered to a patient. This means that enough drug must be given to significantly reduce or eliminate migraine-related pain. In order to preserve drug activity, steps should be taken to inhibit the oxidation of DHE. Preferably, this can be accomplished by dissolving sufficient CO<sub>2</sub> and/or N<sub>2</sub> compositions to retard oxidative degradation and/or including one or more antioxidants. Although any salt form of DHE can be effectively used in compositions, dihydroergotamine mesylate at a concentration of 2 mg/ml or more is preferred. A typical example of a formulation might contain 2 mg/ml of DHE in a vehicle containing glycerin and anhydrous alcohol in sterile water for injection, pH adjusted to 3.6 with methanesulfonic acids/sodium hydroxide. If desired, other agents may also be included in pharmaceutical preparations. For example, the rate at which DHE enters the bloodstream of a patient may be adjusted by including vasodilators or uptake enhancers (e.g., caffeine) in compositions.

The invention also includes a method of treating a patient for the symptoms associated with migraine headache by administering one or more unit doses of the pharmaceutical composition described above. Preferably, compositions will contain dihydroergotamine mesylate and sufficient dissolved CO<sub>2</sub> and/or N<sub>2</sub> to retard its oxidative degradation. Subcutaneous injection is preferred in order to obtain the greatest improvement in the side effect profile, but other routes of delivery may also be used. The total dosage of DHE that will be administered to a patient per migraine attack should generally be between 0.5 mg and 5.0 mg. The term "per migraine attack" refers to the period immediately preceding a migraine headache and extending for about the next twenty-four hours. Since headache may recur, it may be necessary to administer a second therapeutic dose of the drug during this period.

In addition, the invention is directed to a process for preparing a therapeutic package in which the unit dose pharmaceutical composition described above is made and then used to

WO 00/57851

PCT/US00/06657

3

5           prefill a syringe for injection. As used herein, a "prefilled" syringe is one that has been loaded  
with pharmaceutical composition for a period of at least twenty-four hours prior to the time that  
it is administered to a patient. In a preferred embodiment, the prefilled syringes are enclosed  
10           in an opaque, sealed package from which oxygen has been excluded. For example, oxygen may  
5           be displaced with CO<sub>2</sub> and/or N<sub>2</sub>. In addition to including these processes, the present invention  
also encompasses the therapeutic packages that are their end result.

15           A surprising discovery that has been made is that caffeine greatly increases the solubility  
of DHE in aqueous formulations. As a result, compositions having DHE at a concentration of  
10           greater than 4, 5 or 6 mM, can be obtained for administration to patients. Caffeine appears to  
20           be most effective when present in compositions roughly at a weight ratio of between 0.1:1 and  
10:1 relative to DHE. In addition, there are some indications from animal studies that caffeine  
at high concentrations, e.g., at a 10:1 weight ratio relative to DHE improves drug absorption  
25           characteristics, e.g., by producing a more consistent time of absorption.

15           Based upon these findings, the invention is, in another aspect, directed to a  
pharmaceutical composition in unit dose form containing: a) DHE in an amount such that one  
30           or more unit doses are effective in the symptomatic treatment of migraine headache when  
administered to a patient; (b) a pharmaceutically acceptable liquid vehicle in which the DHE  
20           is dissolved at a concentration of at least 2.9 mM; and (c) caffeine at between a 0.1:1 and 10:1  
35           weight ratio relative to DHE. The most preferred composition contains caffeine in a 1:1 weight  
ratio. In order to retard the rate of oxidative degradation of the composition, CO<sub>2</sub> and/or N<sub>2</sub>  
may be dissolved in preparations and one or more antioxidants may be added. Any salt of DHE  
40           may be used but the mesylate salt is generally preferred.

25           The compositions containing caffeine may be used in a method for the symptomatic  
treatment of patients suffering from migraine headache. Preferably, preparations are  
45           administered by subcutaneous injection and, in general, patients will receive a total dosage of  
between 0.5 and 5.0 mg per migraine attack. The compositions may also be used in a process  
30           for preparing a therapeutic package in which a unit dose is present in a prefilled injectable  
50           syringe. As part of the process, the prefilled syringes may be enclosed in an opaque, sealed

55

WO 00/57851

PCT/US00/06657

4

package from which oxygen has been excluded. The invention includes not only these processes for making therapeutic packages but also the packages themselves.

Finally, the invention encompasses improved pharmaceutical compositions and treatment methods involving the combination of DHE at high concentration and caffeine. With respect to unit dose pharmaceutical compositions, the improvement comprises the presence of a concentration of DHE of at least 2 mg/ml; sufficient carbon dioxide and/or nitrogen to retard oxidative degradation; and caffeine at between a 0.1:1 and 10:1 weight ratio relative to DHE. The use of this composition results in an improved method for the symptomatic treatment of a patient suffering from or susceptible to the development of a migraine attack.

#### Brief Description of the Figures

Figure 1: Figure 1 shows a flowchart for the manufacture of 6 liters of a DHE pharmaceutical composition. A unit dose of the formulation contains 2 mg of dihydroergotamine mesylate, USP, in 1.0 ml of glycerin, USP, ethyl alcohol, USP, and water for injection, USP, adjusted to a target pH of 3.6±0.2 with 0.1 M methanesulfonic acid and 0.1 M sodium hydroxide, NF (final concentration of DHE=2.9 mM). The bulk solution is sterile-filtered and then purged with sterile-filtered nitrogen. The solution may be dispensed either into disposable syringes or into 1.0 ml USP Type I ampules under aseptic filling conditions.

Figure 2: Figure 2 shows the mean DHE plasma concentrations obtained in the experiments described in Example 3. Solid triangles=1 mg of Formula A-2 (2 mg/ml, 2.9 mM) sc; solid squares=1 mg Formula A-1 (1 mg/ml, 1.5 mM) sc; open squares=1 mg Formula E-2 (2 mg/ml) sc; open circles=1 mg Formula E-1 (1 mg/ml) sc; and solid diamonds=1 mg DHE 45<sup>®</sup> im.

Figure 3: Figure 3 shows mean plasma DHE concentrations for the experiment described in Example 3. Open circles=1.0 mg DHE 45<sup>®</sup> im (1 mg/ml, 1.5 mM); darkened squares=1.2 mg MT 300 sc (2 mg/ml, 2.9 mM)



WO 00/57851

PCT/US00/06657

5

5

**Detailed Description of the Invention**

10

5

15

Migraine, as defined by the International Headache Society, affects at least 18 million women and 5.6 million men in the United States. Although DHE is known to be an effective treatment for migraine, its value is limited by a tendency to produce unacceptable side effects, particularly nausea. The present invention is based upon the discovery of a new formulation for DHE that, when administered to a migraine patient, maintains efficacy but reduces observed side effects. In addition to being directed to an improved drug formulation, the present invention also encompasses methods by which this formulation is used as well as packaging that should make the use of the formulation more convenient in clinical practice.

10

20

**A. DHE Formulation**

25

15

A formulation has been developed in which DHE is dissolved in a pharmaceutically acceptable liquid at a concentration of at least 2.9 mM. The DHE can be incorporated into formulations in any chemical form and administered to patients either as a free base or as a pharmaceutically acceptable salt. The most preferred formulation contains dihydroergotamine mesylate and caffeine at a 1:1 weight ratio.

30

20

35

40

25

Solutions can be prepared using water or physiologically compatible organic solvents such as ethanol, 1,2-propylene glycol, polyglycols, dimethyl sulfoxide, fatty alcohols, triglycerides, partial esters of glycerin and the like. Parenteral compositions are preferred and may include sterile isotonic saline, water, 1,3-butanediol, ethanol, 1,2-propylene glycol, polyglycols mixed with water, Ringer's solution, etc. In all cases, formulations may be prepared using methods that are standard in the art (see, e.g., *Remington's Pharmaceutical Sciences*, 16th ed., A. Oslo ed., Easton, PA (1980)). In order to prevent the oxidative degradation of DHE, preparations may be sparged with a non-oxidizing gas, e.g., nitrogen and/or CO<sub>2</sub>. If desired, pharmaceutically acceptable antioxidants may also be incorporated into drug preparations. The components present in the most preferred DHE formulation are shown in Table 1 and a procedure for the large-scale preparation of a batch of formula is described in Example 1.

45

50

55

WO 00/57851

PCT/US00/06657

6

Table 1: DHE Formulation

Ingredient <sup>1</sup>	Quantity per Unit Dose	Quantity per Batch of 6 Liters
Dihydroergotamine mesylate, USP	2.0 mg	12.00 g
Glycerin, USP	150.0 mg	900.0 g
Ethyl alcohol 100%, USP	75.0 mg	450.0 g
Sodium Hydroxide, NF	Negligible <sup>2</sup>	Negligible <sup>2</sup>
Methanesulfonic acid	Negligible <sup>2</sup>	Negligible <sup>2</sup>
Water for injection, USP <sup>3</sup>	q.s. to 1.0 ml	q.s. to 6.161 g <sup>3</sup>

<sup>1</sup> = nitrogen and/or CO<sub>2</sub> is used during sparging and filling operations

<sup>2</sup> = 0.1 M methanesulfonic acid or 0.1 M sodium hydroxide, NF solutions are used to adjust the pH to 3.6 ± 0.2

<sup>3</sup> = when formulated by weight, a density of 1.0268 is used to calculate the final weight of the bulk solution

#### B. Treatment Method

The total dosage of DHE administered to a patient should be at least the amount required to reduce or eliminate the pain associated with migraine headache. A single dose will usually be approximately 1 mg. This may be repeated if headache pain is not alleviated or if there is a recurrence of headache. Typically, the total dosage taken by a patient during a migraine episode will be between 0.5 mg and 5.0 mg. These dosages are simply guidelines and may be adjusted for an individual patient based upon clinical conditions and using methods well known in the art.

Although the number of patients experiencing adverse side effects is reduced with the present formulations compared to formulations containing a lower (1.5 mM) concentration of DHE, it is expected that they will still occur. Accordingly, the lowest dosage compatible with headache relief should generally be used. For example, a patient may initially attempt to alleviate pain by administering a dosage of 0.5 mg subcutaneously. If this proves to be insufficient, administration may be repeated. Once an effective dose has been established for a patient, it may be repeated in subsequent migraine attacks. It is generally expected that a

WO 00/57851

PCT/US00/06657

7

dosage of about 1 mg should be sufficient to alleviate headache pain in most patients without producing undesirable side effects. Preparations should not be given in combination with vasoconstrictors, beta blockers, or macrolide antibiotics.

In the most preferred embodiment of this invention DHE is administered subcutaneously. However, alternative routes of administration in which drug is not immediately bioavailable but is instead progressively absorbed into a patient's bloodstream may also be used. Among these alternatives, intramuscular delivery is preferred and nasal, transdermal, intracutaneous, buccal, and sublingual routes may also be used. Specific dosage forms that may be used include aerosols, skin patches, parenterals and sustained release preparations. All dosage forms may be prepared using methods well known in the art (see, e.g., *Remington's Pharmaceutical Sciences*, 16th ed., A. Oslo ed., Easton, PA (1980)). DHE may be administered as either the sole active agent or in combination with other therapeutically active drugs.

### C. Packaging

The DHE formulations described above can be packed in ampules or any other suitable container, but they are preferably provided in prefilled disposable syringes for self-administration by patients, with or without an autoinjector. Typically, each syringe will contain a single dose of DHE. For example, a syringe may contain 1.0 ml of a 2 mg/ml formulation prepared as described above. In order to prevent the oxidative destruction of drug, syringes should be filled under an inert gas such as nitrogen and/or CO<sub>2</sub>. It is also preferred that the syringes be enclosed within a sealed package from which oxygen has been excluded. This may be accomplished by vacuum-packing syringes or by displacing oxygen with nitrogen and/or CO<sub>2</sub>. When an inert gas is used to displace oxygen, packages should be relatively impermeable to diffusion after sealing. Also, the packages should preferably be opaque to ordinary light. Standard methods for filling and packaging syringes are well known in the art and may be used in conjunction with the present invention.

### Examples

#### Example 1: Manufacture of Formulation

Figure 1 is a flowchart for the manufacture of 6 liters (approximately 6,000 ampules or prefilled syringes). In order to carry out the depicted process, the following steps should be followed:

WC 00/57851

PCT/US00/06657

8

5

10

15

20

25

30

35

40

45

50

55

- (a) Depyrogenate glass ampules to be used in the filling process.
- (b) Add 900.0 g of glycerin, USP, to a suitable container.
- (c) Add 450.0 g of ethyl alcohol 100%, USP, to the container.
- (d) Add about 3,500 g of water for injection, USP, to the container.
- (e) Mix until dispersed. Spurge with filtered nitrogen, NF, while mixing.
- (f) While protecting the container from light, charge 12.00 grams of dihydroergotamine mesylate, USP, to the glycerin, ethyl alcohol, and water, and mix until dissolved. Continue to spurge with filtered nitrogen, NF, while mixing.
- (g) Determine the pH of the solution and adjust with 0.1 M methanesulfonic acid or 0.1 M sodium hydroxide, as required, to obtain a pH value of  $3.6 \pm 0.2$ .
- (h) Add a requisite quantity of water to q.s. to 6.161 g and mix while continuing to spurge with filtered nitrogen, NF.
- (i) Determine the pH of the solution and adjust as necessary with 0.1 M methanesulfonic acid or 0.1 M sodium hydroxide to obtain a pH value of  $3.6 \pm 0.2$ .
- (j) Sterile-filter the bulk solution through a sterile 0.22  $\mu$ m filter. At the end of filtration, perform bubble point testing (specification: 45 psi).
- (k) Purge the filtered bulk solution with filtered nitrogen, NF.
- (l) Flush the headspace of the bulk solution with filtered nitrogen, NF, throughout the filling process.
- (m) Fill each sterile 1 ml ampule with  $1.13 \pm 0.02$  g solution.
- (n) Flame-seal each ampule.
- (o) Protect from light.

#### Example 2: Efficacy, Tolerance, and Pharmacokinetics of DHE Formulations

- 25 The objectives of the experiments discussed in this example are to compare the local tolerability and absorption kinetics of experimental preparations of DHE (designated as "MT 300") and a commercially available preparation, DHE 45<sup>®</sup>. Aqueous and ethanol/glycerin/
- 45 water formulations of DHE are tested at concentrations of 1 mg/ml (1.5 mM) and 2 mg/ml (2.9mM). The trial is designed as a randomized, open label, 3-period incomplete crossover
- 50 study of the four different MT 300 treatments, DHE 45<sup>®</sup>, and placebo. In the initial protocol, individual doses of DHE are always 1 mg regardless of the formulation or product. MT 300 and placebo are administered subcutaneously into the upper arm and DHE 45<sup>®</sup> was

WO 00/57851

PCT/US00/06657

9

administered intramuscularly into the deltoid muscle. Safety evaluations included assessment of clinically adverse events throughout the study period and clinical laboratory assessments following each dose. Subjects are also evaluated for any local irritant effects of the various formulations.

Fifteen subjects participate in this study and 16 subjects complete the study. Subjects are divided into three groups and each subject received three treatments. The duration of each treatment period is a single day followed by a washout period of the same length. Serial blood samples for pharmacokinetic analysis are collected for 6 hours after each dose. At least two of the treatments administered to each subject are MT 300. The dosing regimens for the three groups are summarized in Table 2.

Table 2: Dosing Regimen

Group 1 (n=6)	Group 2 (n=7*)	Group 3 (n=5)
Formulation A-1: Aqueous DHE, 1 mg/ml sc	Formulation A-2: Aqueous DHE, 2 mg/ml sc	Formulation E-2: Ethanol/glycerin/water DHE, 2 mg/ml sc
Aqueous placebo, sc	Formulation A-1: Aqueous DHE, 1 mg/ml sc	DHE 45* im
Formulation E-1: Ethanol/glycerin/water DHE, 1 mg/ml sc	Formulation E-2: Ethanol/glycerin/water DHE, 2 mg/ml sc	Formulation A-2: Aqueous DHE, 2 mg/ml sc

\* One subject drops out of the study after the first dose and one subject drops out after the second dose.

#### Results--Exposure

A total of 18 subjects enter this 3-period crossover trial. Because of the limited sample size and crossover design, all formulations of MT 300 are combined for the purpose of describing exposure and tolerance. As shown in Table 3, the 18 subjects treated in this trial actually receive 40 doses of MT 300, 5 doses of DHE 45\*, and 6 doses of placebo.

WO 00/57851

PCT/US00/06657

10

Table 3: Treatment Exposure

	MT 300	DHE 45%	Placebo
Total subjects exposed to single doses	18	5	6
Total number of single doses administered	40	5	6

*Results—Tolerance*

There are no serious adverse events in this study. Two subjects withdraw from the study early due to difficulty with blood sampling required for pharmacokinetic sampling. Mild pain at the injection site occurs in a single subject following administration of the MT 300 formulation, and in two of five patients on DHE 45%. None of the subjects experience more than mild pain.

The higher incidence of pain with DHE 45% may be related to the intramuscular route of administration. The injection site reactions are of little clinical significance. The adverse events experienced are predominantly mild in severity and, overall, the doses of MT 300 may be better tolerated than DHE 45%.

*Results—Pharmacokinetics*

The mean plasma DHE concentration-time profiles following subcutaneous administration of the 1 mg/ml (1.5 mM), formulations of MT 300 (both aqueous and ethanol/glycerin/water vehicles) shows somewhat lower peak plasma levels compared to an intramuscular injection of 1 mg DHE (see Figure 2). These results indicate that the absorption of sc DHE is somewhat less rapid than after im DHE 45%.

In contrast, the mean peak DHE concentrations following subcutaneous administration of both 2 mg/ml (2.9 mM) formulations of MT 300 are approximately 40% to 50% lower than those following either the 1 mg/ml (1.5 mM) formulation of MT 300 or im DHE 45%. Thus, the vehicles do not appear to influence the absorption of DHE while the concentration of DHE in the formulations appear to have an effect. This difference in rate of absorption following the subcutaneous administration of the MT 300, 2 mg/ml formulations may be the result of a local vasoconstrictive action of a high concentration of DHE and/or the smaller surface area for DHE diffusion associated with the smaller volume administered (0.5 ml vs 1 ml).

WO 00/57851

PCT/T/S00/06657

11

**Example 3: Direct Comparison of Tolerance and Pharmacokinetics**

The study described above in Example 2 utilizes an incomplete crossover design. This protocol is amended to provide a direct comparison of the tolerance and pharmacokinetics of a 2 mg/ml (2.9 mM) formulation of MT 300 (Formulation A-2) and DHE 45<sup>®</sup>. The present experiment is a randomized, open-label, two period, parallel group, crossover study comparing subcutaneous administration of 1.2 mg of MT 300 and intramuscular administration of 1 mg of DHE 45<sup>®</sup>. Plasma dihydroergotamine and the 8-hydroxydihydroergotamine metabolite are measured with an LC/MS/MS method, with a LLOQ of 50 pg/ml for both DHE and 8-OH DHE. Serial blood samples are collected for 72 hours after the dose. Seven of 8 subjects complete this study. One subject withdraws from the study due to difficulty in obtaining the blood samples. The adverse event profile is similar to that observed in the study of Example 2.

The mean plasma DHE concentration-time profile is shown in Figure 3. These data confirm the lower peak concentration and more prolonged DHE plasma concentration-time profile observed with the 2 mg/ml (2.9 mM) formulations of MT 300 in the initial protocol. The 72-hour blood sampling period in this study permits a comparison of the extent of exposure for the two treatments. The dose corrected mean AUC-infinity is 8.23(±2.04) ng<sup>·</sup>hr/ml for MT 300 and 9.41(±1.23) ng<sup>·</sup>hr/ml for DHE 45<sup>®</sup>, indicating that the systemic DHE exposure is similar following intramuscular DHE 45<sup>®</sup> (1 mg/ml, 1.5 mM) and subcutaneous MT 300 (2 mg/ml, 2.9 mM). This finding of similarity of bioavailability following intramuscular and subcutaneous administration is consistent with the report by Schran *et al.* (*Clon. Ther. Res.* 35:1501-1508 (1994)). No significant levels of the 8-OH DHE metabolite are found after either treatment.

**Example 4: Overall Tolerance Profile**

Table 4 summarizes the adverse events reported by subjects administered preparations of DHE. Adverse events occur in 26 of 33 subjects treated with MT 300 and 8 of 13 subjects treated with DHE 45<sup>®</sup>. Analysis of the MT 300 tolerance data according to the number of doses administered reveals that the incidence of nausea is relatively low at 8%. The higher incidence of nausea in the DHE 45<sup>®</sup> group suggests a difference in the tolerance of the two products.

WO 09/57351

PCT/US00/06657

12

Table 4: Tolerance Profile of Subjects Administered DHE<sup>1</sup>

	1 mg MT 300 (48 exposures)	1.2 mg MT 300 (7 exposures)	2 mg MT 300 (8 exposures)	A3 MT 300 (63 exposures)	1 mg DHE 45 (13 exposures)
Nausea	4	1	0	5 (8%)	4 (31%)
Light-headedness	1	1	1	3 (5%)	3 (23%)
Leg cramps	0	3	0	3 (5%)	2 (15%)
Headache	1	0	1	2 (3%)	1 (8%)
Muscle pain/ leg pain	3	0	0	3 (5%)	2 (15%)
Heart block <sup>2</sup>	2	0	0	2 (3%)	0
Cold extremities	1	0	0	1 (2%)	1 (8%)
Dizziness	1	0	0	1 (2%)	0
Chest pain	1	0	0	1 (2%)	0
Weakness	0	0	1	1 (2%)	0
Feels high	1	0	0	1 (2%)	0
Fatiness	1	0	0	1 (2%)	0
Tired	0	0	0	0	1 (8%)
Stomach cramps	1	0	0	1 (2%)	0
Vomited	2	0	1	3 (5%)	0

<sup>1</sup> MT 300 preparations are administered subcutaneously and DHE 45 preparations by intramuscular injection.<sup>2</sup> This event occurs in 1 subject after each of two separate doses of MT 300. The subject receives placebo as the second treatment and did not receive DHE 45<sup>®</sup>.



**Claims**

5

10

15

20

25

30

35

40

45

50

55

WO 00/57851

PCT/US00/06657

13

5

*What is Claimed is:*

10

15

20

25

30

35

40

45

50

55

1. A pharmaceutical composition in unit dose form, comprising:
  - a) dihydroergotamine (DHE) in an amount such that one or more unit doses of said composition are effective in the symptomatic treatment of migraine headache when administered to a patient; and
  - b) a pharmaceutically acceptable liquid vehicle in which said DHE is dissolved at a concentration of at least 2.9 mM.
2. The pharmaceutical composition of claim 1, further comprising sufficient dissolved CO<sub>2</sub> and/or N<sub>2</sub> to retard the oxidative degradation of said composition.
3. The pharmaceutical composition of either claim 1 or claim 2, further comprising an antioxidant.
4. The pharmaceutical composition of claim 1, wherein said DHE is present as dihydroergotamine mesylate.
5. A method for the symptomatic treatment of a patient for migraine headache, comprising administering to said patient one or more unit doses of the pharmaceutical composition of claim 1.
6. The method of claim 5, wherein said pharmaceutical composition further comprises sufficient dissolved CO<sub>2</sub> and/or N<sub>2</sub> to retard the oxidative degradation of said composition.
7. The method of claim 5, wherein said DHE is present in said composition as dihydroergotamine mesylate.
8. The method of claim 5, wherein said pharmaceutical composition is administered by subcutaneous injection.

WO 00/57851

PCT/US00/06057

14

5

9 The method of claim 5, wherein said patient is treated with a total dosage of between 0.5 mg and 5.0 mg per migraine attack.

10

10. A process for preparing a therapeutic package comprising:  
(a) preparing a unit dose pharmaceutical composition according to claim 1; and  
(b) prefilling an injectable syringe with said pharmaceutical composition.

15

11. The process of claim 10, wherein said pharmaceutical composition further comprises sufficient CO<sub>2</sub> and/or N<sub>2</sub> to retard the oxidative degradation of said composition.

20

12. The process of claim 10, further comprising enclosing the syringe prefilled with said pharmaceutical composition in an opaque, sealed package from which oxygen has been excluded.

25

13. A therapeutic package produced by the process of either claim 11 or claim 12.

30

14. A therapeutic package which comprises:  
(a) a unit dose pharmaceutical composition according to claim 1; and  
(b) a prefilled, injectable syringe containing said composition.

35

15. The therapeutic package of claim 14, further comprising an opaque, sealed package containing said syringe and from which oxygen has been excluded.

40

16. The therapeutic package of claim 14, wherein said pharmaceutical composition further comprises sufficient CO<sub>2</sub> and/or N<sub>2</sub> to retard the oxidative degradation of said composition.

45

17. In a unit dose pharmaceutical composition containing a solution of DHE and indicated for use in the treatment of migraine, the improvement which comprises:

50

a concentration of DHE in said composition of at least 2 mg/ml and  
carbon dioxide and/or nitrogen dissolved in said composition at a concentration  
sufficient to retard oxidative degradation of said composition.

55

WO 00/57851

PCT/US00/06657

15

5

15. In a method for the symptomatic treatment of a patient suffering from or susceptible to the development of a migraine attack including the use of a pharmaceutical composition of DHE, the improvement which comprises: administering one or more unit doses of the composition according to claim 1.

10

19. A pharmaceutical composition in unit dose form, comprising:

15

- (a) dihydroergotamine (DHE) in an amount such that one or more unit doses of said composition are effective in the symptomatic treatment of a migraine headache when administered to a patient;
- (b) a pharmaceutically acceptable liquid vehicle in which said DHE is dissolved at a concentration of at least 2.9 mM; and
- (c) caffeine at between a 0.1:1 and 10:1 weight ratio with DHE.

20

25

20. The pharmaceutical composition of claim 19, wherein said caffeine is in a 1:1 weight ratio with said DHE.

30

21. The pharmaceutical composition of claim 19, further comprising sufficient dissolved CO<sub>2</sub> and/or N<sub>2</sub> to retard the oxidative degradation of said composition.

35

22. The pharmaceutical composition of claim 19, further comprising an antioxidant.

40

23. The pharmaceutical composition of claim 19, wherein DHE is present as dihydroergotamine mesylate.

45

24. A method for the symptomatic treatment of a patient for migraine headache, comprising administering to said patient one or more unit doses of the pharmaceutical composition of any one of claims 19-23.

50

25. The method of claim 24, wherein said pharmaceutical composition is administered by subcutaneous injection.

55

WO 00/57851

PC1/US00/06657

16

5

26. The method of claim 24, wherein said patient is treated with a total dosage of between 0.5 mg and 5.0 mg of DHE per migraine attack.

10

27. A process for preparing a therapeutic package comprising:
- (a) preparing a unit dose pharmaceutical composition according to any one of claims 19-23; and
  - (b) prefilling an injectable syringe with said pharmaceutical composition.

15

20

28. The process of claim 27, further comprising enclosing the syringe prefilled with said pharmaceutical composition in an opaque, sealed package from which oxygen has been excluded.

25

29. A therapeutic package produced by the process of claim 27.

30

30. A therapeutic package which comprises:
- (a) a unit dose pharmaceutical composition according to any one of claims 19-23; and
  - (b) a prefilled, injectable syringe containing said composition.

35

31. The therapeutic package of claim 30, further comprising an opaque, sealed package containing said syringe from which oxygen has been excluded.

40

32. In a unit dose pharmaceutical composition containing a solution of DHE and indicated for use in treatment of migraine headache, the improvement which comprises:
- (a) a concentration of DHE in said composition of at least 2 mg/ml;
  - (b) carbon dioxide and/or nitrogen dissolved in said composition at a concentration sufficient to retard oxidative degradation of said composition; and
  - (c) caffeine at between a 0.1:1 and 10:1 weight ratio with DHE.

45

50

55

WO 00/57851

PCI/US00/06657

17

5

33. In a method for the symptomatic treatment of a patient suffering from or susceptible to the development of a migraine attack, said method including the use of a pharmaceutical composition of DFE, the improvement which comprises: administering one or more unit doses of the composition according to any one of claims 19-23.

10

15

20

25

30

35

40

45

50

55

WO 00/57851

1 / 2

PCT/US00/06657




Figure 1

W0057851

PCT/US00/06657

2 / 2




Figure 2




Figure 3



## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
5 October 2000 (05.10.2000)

PCT

(10) International Publication Number  
**WO 00/57851 A3**(51) International Patent Classification: A61K 9/08,  
47/02, 47/10, 31/48, A61P 25/06

(21) International Application Number: PCT/US00/06657

(22) International Filing Date: 15 March 2000 (15.03.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/126,333 26 March 1999 (26.03.1999) US(71) Applicant: POZEN INC. [US/US]; Suite 240, 6330  
Quadrangle Drive, Chapel Hill, NC 27514 (US).(72) Inventors: PLACHETKA, John, R.; 321 Silver Creek  
Trail, Chapel Hill, NC 27514 (US). GILBERT, Donna;  
304 Edgewater Circle, Chapel Hill, NC 27516 (US).(74) Agent: SANZO, Michael, A.; Vinson & Elkins L.L.P.,  
2300 First City Tower, 1001 Fannin, Houston, TX 77002-  
6760 (US).(81) Designated States (national): AE, AL, AM, AT, AU, AZ,  
BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE,  
ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,  
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,  
MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,  
SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN,  
YU, ZA, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent  
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent  
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,  
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— With international search report.

(88) Date of publication of the international search report:  
11 January 2001For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

WO 00/57851 A3

(54) Title: HIGH POTENCY DIHYDROERGOTAMINE COMPOSITIONS

(57) Abstract: The present invention is directed to improved formulations for dihydroergotamine in which the drug is present at a concentration of at least 2.9 mM. The invention encompasses methods for using these formulations in treating patients for migraine headaches and the packaging of formulation into prefilled syringes for self-administration by patients.

## INTERNATIONAL SEARCH REPORT

Int: International Application No. PCT/US 00/06657		
A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K9/08 A61K47/02 A61K47/10 A61K31/48 A61P25/06		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) WPI Data, PAJ, CHEM ABS Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 25190 A (OXFORD BIOSCIENCES LTD., GB) 22 August 1996 (1996-08-22) claims 1,4,13-17,22	1,2,5,8, 10-16, 25-31
A	BE 881 967 A (LEK, YU) 16 June 1980 (1980-06-16) claims	1-33
A	EP 0 074 620 A (HOECHST) 23 March 1983 (1983-03-23) claims 1-3,5,6	1-33
A	DE 32 27 122 A (DR. RENTSCHLER) 26 January 1984 (1984-01-26) claims	1-33
-/-		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.		<input checked="" type="checkbox"/> Patent family members are listed in annex.
* Special categories of cited documents:		
*A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another claim or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *Z* document member of the same patent family		
Date of the actual completion of the international search 27 September 2000		Date of mailing of the international search report 04/10/2000
Name and mailing address of the ISA European Patent Office, P.B. 5816 Patendaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 apord, Fax: (+31-70) 340-3018		Authorized officer Scarponi, U

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 00/06657

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DE 25 55 481 A (SANDOZ) 23 June 1977 (1977-06-23) claims ---	1-33
A	FR 2 399 248 A (SANDOZ) 2 March 1979 (1979-03-02) claims -----	1-33

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/06657

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9625190 A	22-03-1996	AU 4671896 A	04-09-1996
		CA 2211572 A	22-08-1996
		EP 0809521 A	03-12-1997
		JP 11500019 T	06-01-1999
		US 6010478 A	04-01-2000
		AU 699463 B	03-12-1998
		AU 4271496 A	19-07-1996
		BG 101600 A	27-02-1998
		BR 9510464 A	29-06-1999
		CZ 9701937 A	12-11-1997
		DE 69511723 D	30-09-1999
		DE 69511723 T	16-03-2000
		EP 0799064 A	08-10-1997
		FI 972554 A	16-06-1997
		GR 3031582 T	31-01-2000
		JP 10512467 T	02-12-1998
		NO 972897 A	20-06-1997
		NZ 297542 A	28-10-1999
		PL 320919 A	10-11-1997
		RU 2135219 C	27-08-1999
		SK 81797 A	04-03-1998
BE 881967 A	16-06-1980	YU 17780 A	31-10-1984
EP 0074620 A	23-03-1983	DE 3136282 A	24-03-1983
		JP 58057322 A	05-04-1983
DE 3227122 A	26-01-1984	AT 39844 T	15-01-1989
		DE 3378892 D	16-02-1989
		EP 0101879 A	07-03-1984
		JP 59033212 A	23-02-1984
DE 2555481 A	23-06-1977	NONE	
FR 2399248 A	02-03-1979	DE 2735587 A	15-02-1979
		AT 364463 B	27-10-1981
		AT 567378 A	15-03-1981
		AU 525725 B	25-11-1982
		AU 3867678 A	07-02-1980
		BE 869560 A	05-02-1979
		CA 1111348 A	27-10-1981
		CH 635347 A	31-03-1983
		CS 203199 B	27-02-1981
		DK 337678 A	07-02-1979
		FI 782341 A	07-02-1979
		GB 1596948 A	03-09-1981
		GR 72791 A	05-12-1983
		IE 47791 B	27-06-1984
		IL 55285 A	13-09-1981
		IT 1202759 B	09-02-1989
		JP 54028811 A	03-03-1979
		NL 7808122 A	08-02-1979
		NO 782605 A, B,	07-02-1979
		NZ 182073 A	19-12-1980
		PH 20356 A	04-12-1986
		PT 68386 A	01-09-1978
		SE 444114 B	24-03-1986
		SE 7808210 A	07-02-1979

Form PCT/ISA210 (patent family annex) (July 1992)

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/06657

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR 2399248 A		US 4138565 A	06-02-1979
		YU 188373 A	29-02-1984
		ZA 7804435 A	26-03-1980

---

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKewed/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**